Lineage Cell Therapeutics, Inc. (LCTX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
LCTX Revenue Growth
Revenue Breakdown (FY 2025)
LCTX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
LCTX Revenue Analysis (2014–2025)
As of May 8, 2026, Lineage Cell Therapeutics, Inc. (LCTX) generated trailing twelve-month (TTM) revenue of $14.6 million, reflecting explosive growth of +130.4% year-over-year. The most recent quarter (Q4 2025) recorded $6.6 million in revenue, up 79.5% sequentially.
Looking at the longer-term picture, LCTX's 5-year compound annual growth rate (CAGR) stands at +79.9%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $14.7 million in 2022.
Revenue diversification analysis shows LCTX's business is primarily driven by Collaboration Revenues (100%). With over half of revenue concentrated in Collaboration Revenues, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including FATE (-51.2% YoY), NTLA (+16.9% YoY), and BEAM (+108.0% YoY), LCTX has outperformed the peer group in terms of revenue growth. Compare LCTX vs FATE →
LCTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LCTXCurrent | $15M | +130.4% | +79.9% | -251.6% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% |
LCTX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $14.6M | +53.2% | $0 | - | $-36,619,000 | -251.6% |
| 2024 | $9.5M | +6.2% | $9.2M | 96.5% | $-21,478,000 | -226.1% |
| 2023 | $8.9M | -39.2% | $8.3M | 92.5% | $-24,733,000 | -276.5% |
| 2022 | $14.7M | +277.4% | $14.0M | 95.0% | $-22,520,000 | -153.2% |
| 2021 | $3.9M | +404.0% | $2.5M | 63.4% | $-49,211,000 | -1263.1% |
| 2020 | $773K | -47.7% | $388K | 50.2% | $-26,447,000 | -3421.3% |
| 2019 | $1.5M | +4.4% | $1.1M | 72.1% | $-38,876,000 | -2630.3% |
| 2018 | $1.4M | -21.0% | $1.1M | 78.7% | $-41,795,000 | -2951.6% |
| 2017 | $1.8M | -20.4% | $1.6M | 90.6% | $-38,902,000 | -2170.9% |
| 2016 | $2.3M | -11.1% | $1.9M | 84.1% | $-58,967,000 | -2618.4% |
See LCTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LCTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LCTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLCTX — Frequently Asked Questions
Quick answers to the most common questions about buying LCTX stock.
Is LCTX's revenue growth accelerating or slowing?
LCTX revenue is accelerating at +130.4% year-over-year, exceeding the 5-year CAGR of +79.9%. TTM revenue reached $15M. Growth momentum has increased versus prior periods.
What is LCTX's long-term revenue growth rate?
Lineage Cell Therapeutics, Inc.'s 5-year revenue CAGR of +79.9% reflects the sustained expansion pattern. Current YoY growth of +130.4% is above this long-term average.
How is LCTX's revenue distributed by segment?
LCTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.